$NBIX
NEUROCRINE BIOSCIENCES INC

2015 Q2 Form 10-Q Financial Statement

#000119312515161293 Filed on April 30, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $0.00 $19.77M $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.600M $5.500M $4.200M
YoY Change 57.14% 30.95% 23.53%
% of Gross Profit
Research & Development $18.72M $16.58M $8.572M
YoY Change 84.22% 93.36% -16.88%
% of Gross Profit
Depreciation & Amortization $300.0K $200.0K $200.0K
YoY Change 50.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $25.32M $22.06M $12.73M
YoY Change 76.32% 73.34% -7.15%
Operating Profit -$25.32M -$2.288M -$12.73M
YoY Change 76.32% -82.02% -1.93%
Interest Expense $500.0K $300.0K $100.0K
YoY Change 150.0% 200.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $1.335M $1.096M $883.0K
YoY Change 36.22% 24.12% -1.89%
Pretax Income -$24.00M -$1.200M -$11.80M
YoY Change 79.1% -89.83% -2.48%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$23.99M -$1.192M -$11.84M
YoY Change 79.26% -89.93% -1.93%
Net Earnings / Revenue -6.03%
Basic Earnings Per Share
Diluted Earnings Per Share -$280.7K -$14.94K -$167.9K
COMMON SHARES
Basic Shares Outstanding 85.42M shares 77.16M shares 67.79M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $384.7M $370.0M $219.9M
YoY Change 97.59% 68.26% 39.0%
Cash & Equivalents $132.1M $170.3M $105.5M
Short-Term Investments $252.7M $199.7M $114.3M
Other Short-Term Assets $4.696M $4.916M
YoY Change
Inventory
Prepaid Expenses
Receivables $30.00M $1.900M
Other Receivables $0.00 $0.00
Total Short-Term Assets $389.4M $405.0M $221.7M
YoY Change 97.1% 82.63% 38.24%
LONG-TERM ASSETS
Property, Plant & Equipment $2.802M $2.543M $1.798M
YoY Change 25.15% 41.43% 0.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $114.2M $115.5M $51.30M
YoY Change 74.89% 125.15% 194.83%
Other Assets $4.800M $4.800M $4.400M
YoY Change 9.09% 9.09% 2.33%
Total Long-Term Assets $121.8M $122.8M $57.56M
YoY Change 69.24% 113.38% 144.64%
TOTAL ASSETS
Total Short-Term Assets $389.4M $405.0M $221.7M
Total Long-Term Assets $121.8M $122.8M $57.56M
Total Assets $511.2M $527.8M $279.3M
YoY Change 89.66% 88.97% 51.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.035M $1.270M $818.0K
YoY Change 22.34% 55.26% -43.97%
Accrued Expenses $12.39M $9.938M $6.111M
YoY Change 66.58% 62.62% -7.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.55M $15.19M $10.61M
YoY Change 45.63% 43.17% -23.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $245.0K $260.0K $260.0K
YoY Change -5.77% 0.0% 71.05%
Total Long-Term Liabilities $245.0K $260.0K $260.0K
YoY Change -5.77% 0.0% 71.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.55M $15.19M $10.61M
Total Long-Term Liabilities $245.0K $260.0K $260.0K
Total Liabilities $44.27M $43.05M $32.24M
YoY Change 35.39% 33.53% -17.27%
SHAREHOLDERS EQUITY
Retained Earnings -$851.5M -$827.5M -$777.6M
YoY Change 7.65% 6.42% 6.27%
Common Stock $86.00K $85.00K $76.00K
YoY Change 13.16% 11.84% 13.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $466.9M $484.7M $247.1M
YoY Change
Total Liabilities & Shareholders Equity $511.2M $527.8M $279.3M
YoY Change 89.66% 88.97% 51.85%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$23.99M -$1.192M -$11.84M
YoY Change 79.26% -89.93% -1.93%
Depreciation, Depletion And Amortization $300.0K $200.0K $200.0K
YoY Change 50.0% 0.0% 0.0%
Cash From Operating Activities $14.00M -$18.20M -$9.800M
YoY Change -241.41% 85.71% -612.55%
INVESTING ACTIVITIES
Capital Expenditures -$500.0K $280.0K $255.0K
YoY Change -16.67% 9.8% 332.2%
Acquisitions
YoY Change
Other Investing Activities -$53.40M -$115.8M -$65.50M
YoY Change -7.45% 76.79% 87.14%
Cash From Investing Activities -$53.90M -$116.1M -$65.70M
YoY Change -7.71% 76.71% 87.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $270.7M $133.2M
YoY Change 103.23% 13688.82%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.800M 273.5M 136.2M
YoY Change 500.0% 100.81% 13999.38%
NET CHANGE
Cash From Operating Activities 14.00M -18.20M -9.800M
Cash From Investing Activities -53.90M -116.1M -65.70M
Cash From Financing Activities 1.800M 273.5M 136.2M
Net Change In Cash -38.10M 139.2M 60.70M
YoY Change -43.97% 129.32% -288.52%
FREE CASH FLOW
Cash From Operating Activities $14.00M -$18.20M -$9.800M
Capital Expenditures -$500.0K $280.0K $255.0K
Free Cash Flow $14.50M -$18.48M -$10.06M
YoY Change -255.91% 83.79% -642.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
85417797 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105532000
CY2014Q1 nbix Cease Use Liability
CeaseUseLiability
2994000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85372303 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85372303 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
10231000
CY2015Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
152000
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15187000
CY2015Q1 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
16800000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
85000
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-179000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1270000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-827497000
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9938000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
484730000
CY2015Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
260000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
527779000
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1312321000
CY2015Q1 us-gaap Liabilities
Liabilities
43049000
CY2015Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1817000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
170262000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2543000
CY2015Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
30030000
CY2015Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
315197000
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
222061000
CY2015Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4831000
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
6611000
CY2015Q1 us-gaap Long Term Investments
LongTermInvestments
115452000
CY2015Q1 us-gaap Assets
Assets
527779000
CY2015Q1 us-gaap Short Term Investments
ShortTermInvestments
199745000
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
206000
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
220000
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
14000
CY2015Q1 us-gaap Other Assets Current
OtherAssetsCurrent
4916000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
404953000
CY2015Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
215450000
CY2015Q1 us-gaap Investments
Investments
315200000
CY2015Q1 nbix Letters Of Credit Collateral
LettersOfCreditCollateral
4600000
CY2015Q1 nbix Number Of Renewal Options
NumberOfRenewalOptions
2 RenewalOptions
CY2015Q1 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3348000
CY2015Q1 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
2086000
CY2015Q1 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
479000
CY2015Q1 nbix Cease Use Liability
CeaseUseLiability
2565000
CY2015Q1 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
13468000
CY2008Q4 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
39100000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44789000
CY2013Q4 nbix Cease Use Liability
CeaseUseLiability
3096000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76465942 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76465942 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
119000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15664000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
76000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-277000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
246000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-826305000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11508000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
208699000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
260000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
243033000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1035205000
CY2014Q4 us-gaap Liabilities
Liabilities
34334000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1877000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31014000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2507000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
200287000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
167462000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4831000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2014Q4 us-gaap Long Term Investments
LongTermInvestments
37492000
CY2014Q4 us-gaap Assets
Assets
243033000
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
162795000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
283000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
283000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4394000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
198203000
CY2014Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
167462000
CY2014Q4 us-gaap Investments
Investments
200300000
CY2014Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3324000
CY2014Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
2211000
CY2014Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
467000
CY2014Q4 nbix Cease Use Liability
CeaseUseLiability
2678000
CY2014Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
14322000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
133200000
CY2007Q4 us-gaap Mortgage Loans On Real Estate Cost Of Mortgages Sold
MortgageLoansOnRealEstateCostOfMortgagesSold
47700000
CY2007Q4 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
61000000
CY2007Q4 us-gaap Sale Leaseback Transaction Gross Proceeds Investing Activities
SaleLeasebackTransactionGrossProceedsInvestingActivities
109000000
CY2007Q4 nbix Number Of Buildings Leased
NumberOfBuildingsLeased
2 Building
CY2007Q4 nbix Sale Leaseback Transaction Lease Period
SaleLeasebackTransactionLeasePeriod
P12Y
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
270700000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
800000 shares
CY2014Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3000000 shares
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9767000
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70260000 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
900000 shares
CY2014Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
100000 shares
CY2014Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
400000 shares
CY2014Q1 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
794000
CY2014Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-617000
CY2014Q1 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
800000
CY2014Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
108907000
CY2014Q1 us-gaap Licenses Revenue
LicensesRevenue
0
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-850000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12725000
CY2014Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-10000
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12041000
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
883000
CY2014Q1 us-gaap Revenues
Revenues
0
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
255000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-11842000
CY2014Q1 us-gaap Investment Income Net
InvestmentIncomeNet
89000
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-199000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2400000
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
12725000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8572000
CY2014Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
6000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
60743000
CY2014Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
178000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
136241000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
136241000
CY2014Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
40000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-65731000
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000000
CY2014Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
43391000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4153000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1127000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2447000
CY2014Q1 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
804000
CY2014Q1 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-102000
CY2014Q1 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
102000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
700000 shares
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES INC
CY2015Q1 dei Trading Symbol
TradingSymbol
NBIX
CY2015Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3900000 shares
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18183000
CY2015Q1 us-gaap Property Management Fee Percent Fee
PropertyManagementFeePercentFee
0.035 pure
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 12px; TEXT-INDENT: 4%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Use of Estimates</i>. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</font></p> </div>
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
80349000 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000914475
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000 shares
CY2015Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
200000 shares
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
700000 shares
CY2015Q1 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
839000
CY2015Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1011000
CY2015Q1 us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
800000
CY2015Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
159221000
CY2015Q1 us-gaap Licenses Revenue
LicensesRevenue
19769000
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
30552000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2288000
CY2015Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
9000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1094000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1096000
CY2015Q1 us-gaap Revenues
Revenues
19769000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
280000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-1192000
CY2015Q1 us-gaap Investment Income Net
InvestmentIncomeNet
257000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
98000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3600000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10231000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
22057000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16575000
CY2015Q1 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-27000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
139248000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
244000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
273525000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
273525000
CY2015Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
9000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-116094000
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2800000
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
43398000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5482000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-546000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3600000
CY2015Q1 nbix Lease Expiration Year
LeaseExpirationYear
2019
CY2015Q1 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
830000
CY2015Q1 nbix Lease Extension Period
LeaseExtensionPeriod
P10Y
CY2015Q1 nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-113000
CY2015Q1 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
113000

Files In Submission

Name View Source Status
0001193125-15-161293-index-headers.html Edgar Link pending
0001193125-15-161293-index.html Edgar Link pending
0001193125-15-161293.txt Edgar Link pending
0001193125-15-161293-xbrl.zip Edgar Link pending
d899476d10q.htm Edgar Link pending
d899476dex101.htm Edgar Link pending
d899476dex311.htm Edgar Link pending
d899476dex312.htm Edgar Link pending
d899476dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
nbix-20150331.xml Edgar Link completed
nbix-20150331.xsd Edgar Link pending
nbix-20150331_cal.xml Edgar Link unprocessable
nbix-20150331_def.xml Edgar Link unprocessable
nbix-20150331_lab.xml Edgar Link unprocessable
nbix-20150331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending